2 recruiting. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow Graves Orbitopathy: new trials by email Literature Review of Graves Orbitopathy trials Research Report on Graves Orbitopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED) linsitinib, Placebo - Thyroid Eye Disease, TED, Graves Orbitopathy | Phase 3 | Recruiting | Sling Therapeutics, Inc. | 130 | 2026-08-04 | 2026-10-20 |
| Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) linsitinib - Thyroid Eye Disease, Graves Orbitopathy | Phase 2 / Phase 3 | Recruiting | Sling Therapeutics, Inc. | 75 | 2023-10-11 | 2025-02-25 |
Graves Ophthalmopathy (2) · Hashimoto Disease (2) · Endocrine System Diseases (1) · Exophthalmos (1) · Eye Diseases (1) · Graves Disease (1) · Orbital Diseases (1) · Thyroid Diseases (1)
Autoimmune Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Eye Diseases, Hereditary (2) · Genetic Diseases, Inborn (2) · Goiter (2) · Hyperthyroidism (2) · Immune System Diseases (2) · Thyroiditis (2) · Thyroiditis, Autoimmune (2) · Endocrine System Diseases (1) · Exophthalmos (1) · Eye Diseases (1) · Graves Disease (1) · Orbital Diseases (1) · Thyroid Diseases (1)
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (2)
United States (2)